Welcome to our dedicated page for AUTOLUS THERAPEUTICS PLC news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on AUTOLUS THERAPEUTICS PLC stock.
Autolus Therapeutics plc (Nasdaq: AUTL) generates frequent news as an early commercial-stage biopharmaceutical company focused on next-generation programmed T cell therapies for cancer and autoimmune disease. News coverage for AUTL often centers on AUCATZYL® (obecabtagene autoleucel; obe-cel), the company’s CD19-directed CAR T cell therapy for adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL), and on the clinical and commercial progress of this product.
Investors and healthcare observers following Autolus news will see updates on AUCATZYL net product revenue, treatment center activation, and reimbursement developments such as NICE recommendations and conditional marketing authorizations in the UK and EU. Press releases also describe real-world data from consortia like ROCCA, which evaluate safety and response rates for AUCATZYL in clinical practice, alongside analyses from the FELIX study that explore CAR T-cell persistence and product cell phenotypes as potential predictors of long-term outcomes.
Autolus regularly reports clinical data from its broader pipeline, including the CATULUS trial in pediatric relapsed or refractory B-ALL, the CARLYSLE Phase 1 study in severe refractory systemic lupus erythematosus, the LUMINA Phase 2 trial in lupus nephritis and the BOBCAT trial in progressive multiple sclerosis. These updates typically highlight remission rates, safety profiles, B-cell depletion and immune reset signals in autoimmune indications. Additional news items cover collaborations, such as the evaluation of Cellares’ automated Cell Shuttle platform to support high-throughput CAR T manufacturing, and corporate developments including leadership appointments and participation in healthcare conferences.
This news page allows readers to track Autolus’ ongoing clinical milestones, regulatory and reimbursement decisions, manufacturing initiatives and financial disclosures related to its T cell therapy programs. For those monitoring AUTL, the flow of updates provides context on how AUCATZYL and pipeline candidates are progressing across hematologic malignancies, solid tumors and autoimmune diseases.
Autolus Therapeutics plc (Nasdaq: AUTL) has announced a public offering of up to $100 million of its American Depositary Shares (ADSs). The offering, managed by J.P. Morgan and Wells Fargo Securities, may include an additional $15 million option for underwriters. This move is part of the company's strategy to support its development of next-generation T cell therapies for cancer. The offering is subject to market conditions, with no assurance regarding completion or terms.
Autolus Therapeutics (Nasdaq: AUTL) will disclose its Q4 2020 and full-year financial results on March 4, 2021, prior to U.S. market open. The company develops next-generation programmed T cell therapies and is expected to provide operational highlights during this release. A conference call will occur at 8:30 am ET, featuring a general business update and an opportunity for investors to engage. For those interested, access to the call will be available via the company’s website and dedicated phone lines.
Autolus Therapeutics plc (Nasdaq: AUTL) is prioritizing its CAR T cell therapy, AUTO1, targeting Adult Acute Lymphoblastic Leukemia (ALL). Key data from the AUTO1-AL1 study is expected in 2022. The company aims to partner its AUTO3 program and adjust its workforce by approximately 20%, anticipating annual cash savings of about $15 million. AUTO1 demonstrated promising results with a 52% event-free survival at 12 months. Autolus is advancing its pipeline focused on oncology, aiming for pivotal data and exploring additional B-cell malignancies.
Autolus Therapeutics plc (Nasdaq: AUTL) announced participation in investor conferences in January 2021. Key events include:
- 11 January 2021 - Presentation at the H.C. Wainwright BioConnect 2021 Conference available on demand from 6:00 am ET.
- 13 January 2021 - Presentation at the 39th Annual J.P. Morgan Healthcare Conference at 9:10 am ET, with virtual meetings and a live webcast.
Archived replays will be accessible for 30 days post-conferences. Autolus develops innovative T cell therapies for cancer treatment.
Autolus Therapeutics (AUTL) announced progress on its CAR T product candidate AUTO3 at the ASH Annual Meeting. The ALEXANDER study, focusing on relapsed/refractory diffuse large B cell lymphoma, showed AUTO3 to be well tolerated, with low rates of cytokine release syndrome and neurotoxicity. The overall objective response rate was 65%, with a complete response rate of 51%. Notably, higher dosing improved outcomes, with an 87% response rate at the highest dose. The company is evaluating a strategy to optimize AUTO3's development path and will provide updates in Q1 2021.
Autolus Therapeutics announced promising results from its AUTO1 CAR T cell therapy in the ongoing ALLCAR Phase 1 study for adult patients with relapsed/refractory B-Acute Lymphocytic Leukemia (ALL). As of November 12, 2020, 20 patients had received AUTO1, showing a tolerance profile with no Grade 3 cytokine release syndrome. Among evaluable patients, 84% achieved minimal residual disease-negative complete response at one month, with encouraging overall survival rates. The pivotal Phase 1b/2 study is anticipated to enroll patients throughout 2021, with full data expected in 2022.
Autolus Therapeutics (AUTL) has announced promising results from a Phase 1 study of AUTO6, a GD2-targeting CAR T therapy. The study demonstrated rapid regression of solid tumors in children without causing neurotoxicity, a common side effect of similar therapies. All six patients in higher dosage cohorts displayed CAR T cell expansion and partial response. The company aims to enhance AUTO6's effectiveness with AUTO6NG, which is expected to enter clinical trials in 2021. The study underscores the potential of CAR T cells against advanced solid cancers, highlighting significant implications for neuroblastoma treatment.
Autolus Therapeutics (Nasdaq: AUTL) announced an upcoming investor conference call to discuss AUTO1 and AUTO3 data from the ASH Virtual Congress 2020. The call will feature Dr. Christian Itin, CEO, who will engage in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 11:25 PM ET. Additionally, on December 7, 2020, the team will present their findings on CAR T cell therapies for adult Acute Lymphoblastic Leukemia and relapsed/refractory diffuse large B cell lymphoma. Webcasts of the events will be available on their website.
Autolus Therapeutics (AUTL) reported its Q3 2020 financial results, highlighting operational progress in clinical trials for AUTO3 and AUTO1 programs. The company presented promising data at the ESMO 2020, showing favorable outcomes for AUTO3 in DLBCL. As of September 30, 2020, cash and equivalents totaled $177.7 million, down from $212.0 million at June 30, 2020. Operating expenses increased to $42.7 million, with R&D expenses rising to $33.5 million from $27.3 million a year earlier. The net loss attributable to shareholders was $37.3 million, compared to $27.2 million in 2019.
Autolus Therapeutics plc (Nasdaq: AUTL) announced its upcoming third quarter 2020 financial results and operational highlights, which will be released before U.S. market opening on November 5, 2020. Management will conduct a conference call at 8:30 AM ET to discuss these results and provide a business update. Interested parties can access the webcast through the company's investor relations page. Details for accessing the call are also provided for both domestic and international callers, along with information for replay after the event.